COMMUNIQUÉS West-GlobeNewswire

-
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
17/07/2024 -
Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
17/07/2024 -
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
17/07/2024 -
Pour la première fois au Moyen-Orient, une chirurgie endoscopique de l'utérus pratiquée au KFSHRC corrige une malformation de la moelle épinière chez un fœtus de 26 semaines
17/07/2024 -
Bon Secours Mercy Health and Philips sign multi-year strategic collaboration
17/07/2024 -
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
17/07/2024 -
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
17/07/2024 -
CervoMed to Participate in the Emerging Growth Conference
17/07/2024 -
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
17/07/2024 -
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
17/07/2024 -
HealthLynked Expands Telemedicine Nationwide
17/07/2024 -
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
17/07/2024 -
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
17/07/2024 -
STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal
17/07/2024 -
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
17/07/2024 -
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
17/07/2024 -
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
17/07/2024 -
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17/07/2024 -
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
17/07/2024
Pages